Generation of porcine PK-15 cells lacking the Ifnar1 or Stat2 gene to optimize the efficiency of viral isolation

PLoS One. 2023 Nov 8;18(11):e0289863. doi: 10.1371/journal.pone.0289863. eCollection 2023.

Abstract

Because pigs are intermediate or amplifying hosts for several zoonotic viruses, the pig-derived PK-15 cell line is an indispensable tool for studying viral pathogenicity and developing treatments, vaccines, and preventive measures to mitigate the risk of disease outbreaks. However, we must consider the possibility of contamination by type I interferons (IFNs), such as IFNα and IFNβ, or IFN-inducing substances, such as virus-derived double-stranded RNA or bacterial lipopolysaccharides, in clinical samples, leading to lower rates of viral isolation. In this study, we aimed to generate a PK-15 cell line that can be used to isolate viruses from clinical samples carrying a risk of contamination by IFN-inducing substances. To this end, we depleted the IFN alpha and beta receptor subunit 1 (Ifnar1) gene or signal transducer and activator of transcription 2 (Stat2) gene in PK-15 cells using the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 method. Treatment of PK-15 cells lacking Ifnar1 or Stat2 with IFNβ or poly (I:C) resulted in no inhibitory effects on viral infection by a lentiviral vector, influenza virus, and Akabane virus. These results demonstrate that PK-15 cells lacking Ifnar1 or Stat2 could represent a valuable and promising tool for viral isolation, vaccine production, and virological investigations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line
  • Interferon Type I* / metabolism
  • Interferon-alpha / metabolism
  • STAT2 Transcription Factor / metabolism
  • Swine
  • Viruses*

Substances

  • STAT2 Transcription Factor
  • Interferon-alpha
  • Interferon Type I

Grants and funding

This work was supported by grants from the Japan Agency for Medical Research and Development (AMED) Research Program on HIV/AIDS JP23fk0410047, JP23fk0410056, JP23fk0410058 (to A.S.); AMED Japan Program for Infectious Diseases Research and Infrastructure JP22wm0325009 (to A.S.); AMED CRDF Global Grant JP22jk0210039 (to A.S.); from JSPS KAKENHI Grant-in-Aid for Scientific Research (B) 22H02500 (to A.S.) and from The Ito Foundation Research Grant R5 Ken77 (to A.S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.